Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (28)	6/1/2000 12:04:00 AM
From: tommysdad	Read Replies (3) \| Respond to of 724

Rick, Can't help you with the on-line version of GenEng -- I get a hardcopy. Just provided the URL without checking it. No mention of Novo deal, or any deal for that matter. States DGI is "currently looking for candidates for stroke (specifically, an IgA agonist), prostate cancer (IgF antagonist), a TNF blocking agent and an agent to block blood coagulation". It reads (like many GenEngNews "articles") like an advertisement for potential collaborators. But it's quite positive and makes the technology sound interesting. A final NBSC note: the back cover advertisement is by "HyClone", which promotes the fact that they use bioreactors from NBSC. Like I know what a bioreactor is.